The treatment of benign thyroid disease.
The treatment of benign forms of thyroid disease is reviewed. Endemic goiter is a public health problem preventable by the addition of iodine to the food or water supply. Endemic and familial goiters are treated with replacement doses of I-thyroxine, as are sporadic colloid goiters and goiters resulting from chronic thyroiditis. Hyperfunctioning autionomous nodules without thyrotoxicosis and cystic nodules require no specific therapy. Prophylaxis against diffuse or nodular goiter after radiation to the head or neck for therapeutic purposes with thyroxine replacement therapy is debatable. All forms of hypothyroidism, including incipient types, require replacement thyroxine therapy, but this should be undertaken cautiously in older patients and in those with evidence of ischemic myocardial disease. Myxedema coma requires vigorous treatment and detailed supervision because of dismal mortality rates. Iodine 131 is the treatment of choice in diffuse toxic goiter, but alternative forms.
D000293:Adolescent; D000328:Adult; D005260:Female; D006042:Goiter / Q000188:drug therapy / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery; D007037:Hypothyroidism / Q000188:drug therapy; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D008713:Methimazole / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011441:Propylthiouracil / Q000009:adverse effects / Q000627:therapeutic use; D011829:Radiation Dosage; D013959:Thyroid Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*; D013974:Thyroxine / Q000627:therapeutic use
D007457:Iodine Radioisotopes; D008713:Methimazole; D011441:Propylthiouracil; D013974:Thyroxine